Načítá se...
Neuropeptide Y improves cisplatin-induced bone marrow dysfunction without blocking chemotherapeutic efficacy in a cancer mouse model
Cisplatin is the most effective and widely used chemo-therapeutic agent for many types of cancer. Unfortunately, its clinical use is limited by its adverse effects, notably bone marrow suppression leading to abnormal hematopoiesis. We previously revealed that neuropeptide Y (NPY) is responsible for...
Uloženo v:
| Vydáno v: | BMB Rep |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Korean Society for Biochemistry and Molecular Biology
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5595171/ https://ncbi.nlm.nih.gov/pubmed/28712386 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5483/BMBRep.2017.50.8.099 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|